ID24264A - COMPOSITION CONSIST OF 5- [4- [2- (N-METHYL-N-2-PYRIDYL) AMINO) ETHOCYSIE [BENZIL] TIAZOLIDIN-2,4-DION - Google Patents

COMPOSITION CONSIST OF 5- [4- [2- (N-METHYL-N-2-PYRIDYL) AMINO) ETHOCYSIE [BENZIL] TIAZOLIDIN-2,4-DION

Info

Publication number
ID24264A
ID24264A IDW991520A ID991520A ID24264A ID 24264 A ID24264 A ID 24264A ID W991520 A IDW991520 A ID W991520A ID 991520 A ID991520 A ID 991520A ID 24264 A ID24264 A ID 24264A
Authority
ID
Indonesia
Prior art keywords
ethocysie
tiazolidin
dion
benzil
pyridyl
Prior art date
Application number
IDW991520A
Other languages
Indonesian (id)
Inventor
Jeffrey Roger Granett
Original Assignee
Smithkline Beecham P L C Cs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham P L C Cs filed Critical Smithkline Beecham P L C Cs
Publication of ID24264A publication Critical patent/ID24264A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IDW991520A 1997-06-05 1998-06-02 COMPOSITION CONSIST OF 5- [4- [2- (N-METHYL-N-2-PYRIDYL) AMINO) ETHOCYSIE [BENZIL] TIAZOLIDIN-2,4-DION ID24264A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
PCT/EP1998/003478 WO1998055122A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
ID24264A true ID24264A (en) 2000-07-13

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991520A ID24264A (en) 1997-06-05 1998-06-02 COMPOSITION CONSIST OF 5- [4- [2- (N-METHYL-N-2-PYRIDYL) AMINO) ETHOCYSIE [BENZIL] TIAZOLIDIN-2,4-DION

Country Status (29)

Country Link
EP (1) EP0998284A1 (en)
JP (1) JP2001521553A (en)
KR (1) KR20010013410A (en)
CN (3) CN1526391A (en)
AP (1) AP1214A (en)
AR (2) AR008198A1 (en)
AU (1) AU8215098A (en)
BG (1) BG104048A (en)
BR (1) BR9810405A (en)
CA (2) CA2333352A1 (en)
CO (1) CO4940400A1 (en)
DZ (1) DZ2510A1 (en)
EA (1) EA002384B1 (en)
GB (1) GB9711683D0 (en)
HU (1) HUP0004070A3 (en)
ID (1) ID24264A (en)
IL (1) IL133074A0 (en)
MX (1) MXPA99011322A (en)
NO (2) NO995938L (en)
NZ (2) NZ523725A (en)
OA (1) OA11306A (en)
PE (1) PE78899A1 (en)
PL (1) PL337201A1 (en)
SK (1) SK164899A3 (en)
TR (2) TR200002790T2 (en)
TW (1) TW570797B (en)
UY (1) UY25032A1 (en)
WO (1) WO1998055122A1 (en)
ZA (2) ZA9811572B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
CN1208335C (en) 1999-04-23 2005-06-29 史密丝克莱恩比彻姆有限公司 Thiazolidinedione derivative and its use as antidiabetic
IL146111A0 (en) * 1999-04-23 2002-07-25 Smithkline Beecham Plc 5-[4-[2-(n-methyl-n-(2-pyridyl) amino)ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
DE06252444T8 (en) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N- {5 - [[4- [2- (Methyl-2-pyridinylamino) -ethoxy] -phenyl] -methyl] -2,4-thiazolidinedione-succinic acid, method of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (en) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituted thiazolidinedione derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
MX9603338A (en) * 1994-02-10 1997-03-29 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases.
CN1192683A (en) * 1995-08-10 1998-09-09 沃尼尔·朗伯公司 Method for reducing amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
AU3552697A (en) * 1996-07-12 1998-02-09 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
ZA984826B (en) 1999-08-03
ZA9811572B (en) 1999-07-22
JP2001521553A (en) 2001-11-06
AP9901696A0 (en) 1999-12-31
WO1998055122A1 (en) 1998-12-10
PL337201A1 (en) 2000-08-14
HUP0004070A2 (en) 2002-02-28
NO995938D0 (en) 1999-12-03
TR200002790T2 (en) 2001-11-21
EA199901116A1 (en) 2000-06-26
PE78899A1 (en) 1999-10-22
OA11306A (en) 2003-10-22
KR20010013410A (en) 2001-02-26
CN1259050A (en) 2000-07-05
CO4940400A1 (en) 2000-07-24
CA2292629C (en) 2004-01-06
BG104048A (en) 2000-07-31
AR008198A1 (en) 1999-12-29
AU8215098A (en) 1998-12-21
DZ2510A1 (en) 2003-01-25
GB9711683D0 (en) 1997-08-06
EA002384B1 (en) 2002-04-25
AR015120A1 (en) 2001-04-18
AP1214A (en) 2003-10-08
CN1430959A (en) 2003-07-23
NZ513922A (en) 2001-09-28
CA2292629A1 (en) 1998-12-10
EP0998284A1 (en) 2000-05-10
HUP0004070A3 (en) 2002-03-28
IL133074A0 (en) 2001-03-19
TW570797B (en) 2004-01-11
NZ523725A (en) 2004-09-24
UY25032A1 (en) 1998-11-26
SK164899A3 (en) 2000-11-07
CA2333352A1 (en) 1998-12-10
BR9810405A (en) 2000-08-29
TR199902963T2 (en) 2000-02-21
NO20040738L (en) 2000-02-02
NO995938L (en) 2000-02-02
CN1526391A (en) 2004-09-08
MXPA99011322A (en) 2004-12-02
CN1112926C (en) 2003-07-02

Similar Documents

Publication Publication Date Title
DK0925287T3 (en) Heterocyclic metalloprotease inhibitors
ATE267805T1 (en) LACTAM COMPOUNDS AS METALLOPROTEASE INHIBITORS
DK0923561T3 (en) Heterocyclic metalloprotease inhibitors
ATE485283T1 (en) TYPE 1 11-BETA-HYDROXY-STEROID DEHYDROGENASE INHIBITORS
DE69940115D1 (en) HETEROCYCLIC INHIBITORS OF P38
NO20021116D0 (en) New composition
DE69830410D1 (en) META BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS
DK1114051T3 (en) Inhibitors of p38
MA26500A1 (en) NEW FORM OF S-OMERPRAZOLE
EE200200132A (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
NO990548L (en) Inhibitors of cysteine protease
NO20021115D0 (en) New composition
DE60009675D1 (en) COMPOSITION CONTAINING PROTON PUMP INHIBITORS
ID24264A (en) COMPOSITION CONSIST OF 5- [4- [2- (N-METHYL-N-2-PYRIDYL) AMINO) ETHOCYSIE [BENZIL] TIAZOLIDIN-2,4-DION
ATE333866T1 (en) DISPERSION FORMULATIONS CONTAINING LIPASE INHIBITORS
DK0928291T3 (en) 3-Mercaptoacetylamino-1,5-substituted 2-oxo-azepane derivatives useful as inhibitors of matrix metalloproteinase
ID24677A (en) COMBINATION OF FUNICIDAL ACTIVE COMPOUNDS
ID24267A (en) ENANSIOMERS OF 4 - [[(SIANOIMINO) [(1,2,2-TRIMETHYLOPOPIL) AMINO] METHYL] AMINO] BENZONITRIL
DK199901730A (en) New Composition
DK0928192T3 (en) High-release active substance antimycotic gel
DK0888340T3 (en) 4- (Benzo-1,3-dioxolyl) -pyrrolidine-3-carboxylic acid derivatives as antagonists of enodthelin
ID24081A (en) COMPOUNDS 5- (2-IMIDAZOLINILAMINO) BENZIMIDAZOL USING AS ALFA-2-ADRENOSEPTOR AGONISTS
ATE525362T1 (en) 2-(3-(4-(2-T-BUTYL-6-TRIFLUORMETHYLPYRIMIDINE-4-
DK0944601T3 (en) Heterocyclic quanidinylamino compounds as alpha-2-adrenoceptor agonists
DE60034215D1 (en) SURFACE ACTIVE COMPOSITION